Europe Biomarkers Market

The Europe biomarkers market is forecasted to grow to USD 28.11 billion by 2030 as compared to USD 17.46 billion in 2025, with a CAGR of 10.0% during the forecast period. The Europe biomarkers market growth is primarily attributed to the rising incidence of chronic diseases and the growing adoption of personalized and precision medicine, both enabled by genomics advancements.

To know about the assumptions considered for the study download the pdf brochure

There are several key players in the Europe biomarkers market, such as F. Hoffmann-La Roche Ltd. (Switzerland), Merck KGaA (Germany), Qiagen (Germany), Eurofins Scientific (Luxembourg), Biomérieux (France), R Biopharm AG (Germany), Life Sciences BV (Netherlands), and Proteome Sciences (UK), among others. Companies in this industry are implementing plans to increase their global visibility and expand their product lines. In January 2025, bioMérieux acquired SpinChip Diagnostics to strengthen its immunoassay and point-of-care testing capabilities, with a focus on cardiovascular biomarker detection. With this acquisition, bioMérieux is broadening its diagnostics portfolio and expanding biomarker-based testing at ultra-high sensitivity in acute care ?‍?‌‍?‍‌?‍?‌‍?‍‌?‍?‌‍?‍‌?‍?‌‍?‍‌units.

F. Hoffmann-La Roche Ltd. (Switzerland) remains a leader in the European biomarkers market, with a comprehensive diagnostic portfolio and seamless integration of biomarker development into precision medicine. The company holds the distinction of being the first to use companion diagnostics in oncology, immunology, and cardiovascular diseases, a position further supported by mutually beneficial partnerships with European hospitals, laboratories, and academic centers. Roche's continued investment in advanced molecular diagnostics, digital pathology, and molecular personalized healthcare platforms is a major factor consolidating its presence in Europe.  

Merck KGaA (Germany) retains its significant position in Europe's biomarker market due to its broad portfolio of life science tools that support biomarker discovery, validation, and assay development. The company plays a crucial role in pharmaceutical and biotech R&D workflows by providing essential components, including reagents, antibodies, and analytical solutions. Additionally, Europe's growing trends in precision medicine and translational research support Merck's ability to maintain its market position, particularly in Germany, the UK, and France.

Eurofins Scientific (Luxembourg) is a key contributor with a significant share of the biomarkers market in Europe. Through its numerous clinical testing, bioanalytical, and laboratory services locations, the company supports biomarker research and clinical validation during drug development, diagnostics, and clinical trials. Equipped with a wide range of offerings, regulatory expertise, and a presence in various European countries, Eurofins is well-positioned to promote the use of biomarkers for drug development and diagnostic issuance.

Market Ranking

The Europe biomarkers market is consolidated, supported by strong clinical research infrastructure, widespread adoption of precision medicine, and high investments in diagnostics and life sciences across major countries such as Germany, France, the UK, and Switzerland. F. Hoffmann-La Roche Ltd. remains a major player in Europe, driven by its dominant in vitro diagnostics portfolio and strong position in companion diagnostics for oncology and chronic disease management. Merck KGaA holds a strong market position due to its broad portfolio of life science tools and reagents that support biomarker discovery, validation, and translational research across pharmaceutical, biotech, and academic institutions. Eurofins Scientific is a competitor through its extensive network of laboratory and bioanalytical services, enabling biomarker testing and clinical validation across drug development and diagnostics. Across Europe, demand for clinically validated, regulatory-compliant, and scalable biomarker solutions continues to support large, well-established players with integrated capabilities.

Related Reports:

Europe Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)- Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com